P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL
J. Panse,
N. Daguindau,
S. Okuyama,
R. Peffault de Latour,
P. Schafhausen,
N. Straetmans,
M. Al-Adhami,
T. Ajayi,
E. Persson,
M. Yeh,
R. Wong
Affiliations
J. Panse
1 Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
N. Daguindau
2 Hematology Department, CH Annecy Genevois, Annecy, France
S. Okuyama
3 Hematology/Oncology Division, Denver Health Medical Center, Denver, United States of America
R. Peffault de Latour
4 French Reference Center for Aplastic Anemia and Paroxysmal Noctural Hemoglobinuria, Assistance Publique - Hôpitaux de Paris; Université de Paris, Paris, France
P. Schafhausen
5 Medical Clinic and Polyclinic II - Hematology, Oncology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
N. Straetmans
6 Department of Hematology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
M. Al-Adhami
7 Apellis Pharmaceuticals, Inc., Waltham, United States of America
T. Ajayi
7 Apellis Pharmaceuticals, Inc., Waltham, United States of America
E. Persson
8 Swedish Orphan Biovitrum AB, Stockholm, Sweden
M. Yeh
7 Apellis Pharmaceuticals, Inc., Waltham, United States of America
R. Wong
9 Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong
